Advertisment
|
|
|
news roundup
OmniComm's TrialMaster EDC suite will be used for the CRO's collection of clinical data in trials spanning all clinical phases and therapeutic areas.
|
|
advertisment
BIOVISUALIZATION
Effective Mining and Interpretation of Laboratory Results Data
LIVE WEBCAST: Thursday, May 26, 2016 at 10 am PDT / 12 pm CDT / 1 pm EDT
 Free registration
|
|
Montrium announced the global availability of its eTMF Navigator, an interactive dashboard integrated into its eTMF Connect.
|
|
advertisment
ICH E6 (R2) Process and Technology Considerations for the New Risk Based Gold Standard
LIVE WEBCAST: Thursday, May 12, 2016 11:00 am EDT
 Free registration
|
|
The platform gives sponsors the ability to build and review their protocol's schedule of events in a standardized format, which can be centrally built and shared and reused by multiple sites on the same protocol.
|
|
advertisment
Keeping pace with immuno-oncology research breakthroughs and biomarker identification
Live webinar: Wednesday, May 4, 2016 11 am EDT (8 am PDT)
 Register now
|
|
|
|
advertisment
|
|
Subscribe
|
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
Advertisment
|
|
|
RBM
With the introduction centralized monitoring in a risk-based monitoring (RBM) approach, the central monitor is emerging as a key and important role.
|
|
advertisment
From eligibility to exploratory: Planning and implementing biomarker testing for Immuno-oncology trials
On Demand
 Learn More
|
|
This exploratory case study illustrates how RBM can be applied using a specific technology solution, and examines both data-driven models and centralized manual data review.
|
|
advertisment
Immuno-Oncology Insights:
Top 5 Challenges in Today's Immuno-Oncology Trials
On Demand
 Learn More
|
|
|
|
Articles
This article explores how study site-enabled patient-centric platforms can improve depressed patient behavioral outcomes in clinical trials.
|
|
Blog Posts
A group of senior European oncologists have expressed their strong opposition to the Brexit (British Exit) campaign, in advance of the referendum.
|
|
|
advertisment
Overcoming regulatory and statistical hurdles of biosimilars drug development
On Demand
 Learn More
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
